Saturday 17 October 2026
Export NGNE’s income statement to Excel — free account
Neurogene Inc.
NGNE Healthcare Biotechnology
Neurogene Inc.’s revenue for fiscal 2024 (year ended December 2024) was $925,000.00. In the quarter to June 2026, EPS fell 45.7%, free cash flow fell 23.0% and total debt fell 66.7%, each against the same quarter a year earlier.
23.27
0.68
−2.84%
Follow NGNE
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | — | — | — | — | — | 0.00 | — | — |
Altman Z-Score |
— | 8.68 | — | — | — | — | — | 2.07 | — | — |
P/S ratio |
— | 0.00 | — | — | — | — | — | 0.00 | — | — |
P/FCF ratio |
— | 0.00 | — | — | — | — | — | 0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
— | 14.53 | — | — | — | — | — | 9.07 | — | — |
P/Operating CF |
— | (22.95) | — | — | — | — | — | (5.20) | — | — |
P/B ratio |
— | 1.29 | — | — | — | — | — | 0.70 | — | — |
Price to Tangible BV |
— | 1.29 | — | — | — | — | — | 0.70 | — | — |
EV/Sales |
— | 0.00 | — | — | — | — | — | 0.00 | — | — |
EV/EBITDA |
— | 0.00 | — | — | — | — | — | 0.80 | — | — |
EV/Operating CF |
— | (1.26) | — | — | — | — | — | 0.83 | — | — |
EV/FCF |
— | (1.25) | — | — | — | — | — | 0.83 | — | — |
Quick Ratio |
16.39 | 20.61 | 8.58 | 12.33 | 16.50 | 24.41 | 30.17 | 16.68 | 9.93 | 10.87 |
Current Ratio |
16.56 | 20.84 | 8.72 | 12.74 | 16.67 | 24.66 | 30.28 | 16.68 | 9.93 | 10.87 |
Net Debt/EBITDA |
2.57 | 3.82 | 3.76 | 1.54 | 2.44 | 6.03 | 2.03 | 2.38 | 2.13 | 2.74 |
Debt/Assets |
0.00% | 0.01% | 0.03% | 0.06% | 0.04% | 0.05% | 0.10% | 0.01% | 0.03% | 0.03% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.27 | 0.00 | 0.00 |
Operating CF/Net income |
0.85 | 0.94 | 1.42 | 0.96 | 0.78 | 0.74 | 0.22 | 1.00 | 0.89 | 0.82 |
Capex/Depreciation |
0.82 | (0.98) | (0.10) | (0.70) | (1.43) | (1.22) | (1.66) | (0.17) | (1.37) | 0.00 |
Interest Coverage |
(20,665.60) | (6,883.75) | (4,631.92) | (28,258.50) | (3,194.63) | (68.83) | (46.02) | (8,156.00) | (12,779.75) | (37,645.00) |
| (31.41%) | (30.28%) | (180.30%) | 3,839.23% | (36.33%) | (19.99%) | (64.79%) | (36.82%) | (41.21%) | (29.24%) | |
| (28.94%) | (26.92%) | (21.89%) | (40.50%) | (32.47%) | (18.61%) | (61.82%) | (33.61%) | (37.92%) | (27.64%) | |
ROIC |
0.00% | 0.00% | 0.00% | (211.87%) | (8,175.92%) | 0.00% | 0.00% | 0.00% | 0.00% | (56.49%) |
Return on Tangible Assets |
(33.69%) | (23.77%) | (18.67%) | (56.21%) | (42.80%) | (17.50%) | (49.28%) | (43.30%) | (50.81%) | (39.03%) |
Average Days of Receivables |
— | 0.00 | — | — | — | — | 0.00 | 3.46 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 6,585.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 167.16% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 2,444.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 63.34% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 899.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 18.79% | 0.00% | 0.00% |
Graham Net Nets |
— | 0.72 | — | — | — | — | — | 1.42 | — | — |
Graham Number |
— | 0.00 | — | — | — | — | — | 0.00 | — | — |
Earnings Yield |
— | (18.68%) | — | — | — | — | — | (62.04%) | — | — |
Free Cash Flow Yield |
— | (17.78%) | — | — | — | — | — | (62.25%) | — | — |
Revenue per Share |
0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.26 | 0.00 | 0.00 |
Operating CF per Share |
(3.62) | (4.02) | (104.52) | (133.73) | (17.28) | (9.48) | (11.39) | (26.85) | (38.14) | (32.00) |
Capex per Share |
(0.06) | (0.05) | (0.65) | (5.65) | (1.19) | (0.86) | (0.65) | (0.04) | (0.42) | (0.75) |
Free Cash Flow per Share |
(3.67) | (4.07) | (105.17) | (139.38) | (18.47) | (10.34) | (12.04) | (26.89) | (38.56) | (32.75) |
Cash per Share |
12.61 | 17.78 | 400.73 | 207.65 | 51.77 | 74.31 | 105.88 | 65.42 | 92.18 | 109.09 |
Shareholders Equity per Share |
12.42 | 17.67 | 378.10 | 249.69 | 51.91 | 73.79 | 104.84 | 61.80 | 84.34 | 153.13 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
12.42 | 17.67 | 378.10 | 249.69 | 51.91 | 73.79 | 104.84 | 61.80 | 84.34 | 153.13 |
Free Cash Flow |
(78.36) | (71.41) | (51.74) | (55.05) | (50.82) | (26.79) | (16.27) | (31.63) | (45.21) | (30.94) |
Working Capital |
255.36 | 300.77 | 177.38 | 78.07 | 135.35 | 186.63 | 138.85 | 72.54 | 97.87 | 93.97 |
Capital Expenditures |
(1.18) | (0.81) | (0.32) | (2.23) | (3.26) | (2.22) | (0.88) | (0.05) | (0.49) | (0.71) |
Net Current Asset Value |
248.05 | 290.57 | 163.80 | 74.08 | 123.59 | 175.22 | 138.26 | 72.22 | 97.38 | 93.77 |
EV/EBIT |
— | 0.00 | — | — | — | — | — | 0.80 | — | — |
Capex to Sales |
0.00 | 0.87 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | — | — | — | — | — | 0.00 | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(0.11) | 0.05 | 0.19 | 0.16 | 0.35 | 0.51 | 0.26 | 0.72 | 0.40 | 0.00 |
Cash ROIC |
(14.68%) | (11.47%) | (13.50%) | (30.46%) | (17.81%) | (6.98%) | (5.71%) | (21.14%) | (21.84%) | (12.49%) |
Accounts Receivable Turnover |
— | 0.00 | — | — | — | — | 0.00 | 51.18 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | — | — | — | — | 0.37 | 0.49 | 0.58 | 0.37 |
Average Payables |
1.64 | 1.97 | 1.61 | 4.02 | 7.30 | 5.65 | 4.37 | 7.79 | 10.24 | 7.16 |
Average Assets |
312.17 | 279.15 | 165.92 | 136.26 | 186.89 | 178.77 | 112.32 | 93.97 | 132.35 | 133.86 |
Average Common Equity |
287.63 | 248.20 | 20.14 | (1.44) | 167.04 | 166.45 | 107.18 | 85.78 | 121.78 | 126.54 |
Columns are period end dates